Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

Impact · against what's priced in

Capricor Therapeutics is providing updated clinical data for deramiocel in Duchenne Muscular Dystrophy, which serves as a positive catalyst for the lead candidate's viability. The news focuses on open-label extension data, providing evidence of efficacy and safety that supports the company's path toward potential approval.

CAPR+0.40: No priced-in read yet

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

How each ticker is affected

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

How each ticker is affected

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Track these names every morning.

Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy

Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

Small Cap Watch: AuMEGA, Lightning Minerals and Noxopharm advance key programs

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

How each ticker is affected

Next reads from the same story arc

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

How each ticker is affected

Next reads from the same story arc

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Track these names every morning.

Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy

Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

Small Cap Watch: AuMEGA, Lightning Minerals and Noxopharm advance key programs